Organisation paid for research Program year 2023 Source: CMS Open Payments

Temple Univ

Neither a doctor nor a teaching hospital

Research payments

$340,050

40 payments

Through program year 2023, Temple Univ is reported as receiving $340,050 in research payments, across 40 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $113,701 6
2022 Research $117,738 12
2021 Research $81,641 12
2020 Research $21,773 6
2019 Research $5,196 4

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $225,981 33 payments
  2. Siemens Medical Solutions USA, Inc. $101,412 3 payments
  3. AstraZeneca UK Limited $12,657 4 payments
Studies the money was for Research payments · program years 2019–2023
  1. Preeclampsia Assays OUS Collection $61,158 2 payments
  2. A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States $59,444 1 payment
  3. PE OUS Collection Study $40,254 1 payment
  4. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 $35,757 4 payments
  5. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $29,611 6 payments
  6. A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 $24,703 2 payments
  7. Tracking treatment pathways in adult patients with hyperkalemia (TRACK) $20,420 1 payment
  8. A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID 19 $18,254 2 payments
  9. The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $12,657 4 payments
  10. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $10,351 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record